Website
View WebsiteOffice Location
Wisconsin Institute Medical Research
1111 Highland Ave 6151
Dr. Andrea Galmozzi is a faculty member of the Division of Endocrinology, Diabetes and Metabolism within the Department of Medicine. Throughout his training, he has published 22 peer-reviewed articles; he was a recipient of various awards, including Italian Institute of Health and American Heart Association predoctoral and postdoctoral fellowships, respectively. In 2019, was invited to present at the Rising Stars Lecture Series at NIH. Dr. Galmozzi serves as reviewer for several peer-reviewed scientific journals.
University of Milan, Milan, Italy – PhD, Biochemistry
The Scripps Research Institute, La Jolla, California – Postdoctoral Fellow/Staff Scientist
- White and brown adipose tissue share a convergent fibro-adipogenic progenitor population
- White and Brown Adipose Tissue Share a Common Fibro-Adipogenic Progenitor Population
- Dose-dependent dual effects of HDAC inhibitors on glial inflammatory response
- Haem biosynthesis regulates BCAA catabolism and thermogenesis in brown adipose tissue
- Fast and deep phosphoproteome analysis with the Orbitrap Astral mass spectrometer
- Heme biosynthesis regulates BCAA catabolism and thermogenesis in brown adipose tissue
- Fast and Deep Phosphoproteome Analysis with the Orbitrap Astral Mass Spectrometer
- Deconstructing Adipose Tissue Heterogeneity One Cell at a Time
- Pharmacologic IRE1/XBP1s activation promotes systemic adaptive remodeling in obesity
- Metabolomics activity screening of T cell-induced colitis reveals anti-inflammatory metabolites
- Isolation and Differentiation of Primary White and Brown Preadipocytes from Newborn Mice
- Discovery of small-molecule enzyme activators by activity-based protein profiling
- Activation of Kappa Opioid Receptor Regulates the Hypothermic Response to Calorie Restriction and Limits Body Weight Loss
- PGRMC2 is an intracellular haem chaperone critical for adipocyte function
- Intestinal bitter taste receptor activation alters hormone secretion and imparts metabolic benefits
Dr. Galmozzi’s research focuses on the identification of adipocyte functional pathways that can be pharmacologically modulated to treat metabolic disorders, including obesity and type 2 diabetes. His primary research interest is to understand how signaling metabolites, particularly endogenous ligands of nuclear receptors, are trafficked inside cells. He carries out this goal using a multidisciplinary approach encompassing physiology, chemical biology (chemoproteomics, metabolomics), molecular and cellular biology, and in vivo models of metabolic disease. Elucidation of the molecular pathways that traffic signaling metabolites will shed light on the crosstalk between metabolism and gene transcription, reveal fundamental mechanisms in cell biology and open up new avenues to modulate gene expression for therapeutic purposes.
Wisconsin Partnership Program New Investigator Award (2022)
UW Institute for Clinical and Translational Research Award (2021)
Washington University Diabetes Research Center Award (2021)
American Heart Association Postdoctoral Fellowship (2014)